Fig. 4From: Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trialsThe pooled weighted mean differences of the reduction of MHDs in treatment group compared with placebo in different doses, the diamond indicates the estimated relative risk with 95% confidence interval for the pooled patients. WMD weighted mean differencesBack to article page